GORT

Reviews

Ivosidenib: A Review In Advanced Cholangiocarcinoma

Di: Everly

Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic ...

Our data suggest that ivosidenib is a well tolerated option for the treatment of mIDH1 advanced cholangiocarcinoma, and might offer patients some clinical benefit in this molecularly defined

Abstract. Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review

Interpretation: Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivosidenib was well tolerated. This study shows the clinical benefit of targeting

2021 Year in Review – Cholangiocarcinoma Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation. Cholangiocarcinoma. 2021 Year in

Ivosidenib is under clinical evaluation in a phase 1 study that aims to assess its safety and tolerability in patients with mIDH1 solid tumours. Here we report data for the mIDH1

  • Ivosidenib: A Review in Advanced Cholangiocarcinoma
  • New systemic treatment options for advanced cholangiocarcinoma
  • Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
  • Ivosidenib Induces OS Benefit in Advanced IDH1+ Cholangiocarcinoma

Ivosidenib (Tibsovo®), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the treatment of adults

ABSTRACT. Cholangiocarcinoma (CCA) is a rare and aggressive cancer with a poor prognosis. Ivosidenib, an orally administered, first-in-class small-molecule inhibitor, targets the mutated

These data, coupled with supportive quality of life data and a tolerable safety profile, demonstrate the clinical benefit of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation.

January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the

Ivosidenib (Tibsovo®), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the

Our data suggest that ivosidenib is a well tolerated option for the treatment of mIDH1 advanced cholangiocarcinoma, and might offer patients some clinical benefit in this molecularly defined population.

To report the final overall survival (OS) results from the ClarIDHy trial, which aimed to demonstrate the efficacy of ivosidenib (AG-120)—a first-in-class, oral, small-molecule inhibitor

  • FDA Approval Summary: Ivosidenib for the treatment of patients with
  • Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
  • Targeted Agents Show Promise in Cholangiocarcinoma
  • Treatment of IDH1-Mutant cholangiocarcinoma
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma

Ivosidenib is a potent, oral inhibitor of mutated IDH1. In a phase 1 dose-escalation and expansion study, ivosidenib showed promising progression-free survival and overall

Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest James E. Frampton is a salaried employee of Adis

Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic

Ivosidenib was also found to result in a statistically significant improvement in progression-free survival (PFS) vs placebo per independent review committee assessment

Final Results from the ClarIDHy Phase III Study of Ivosidenib Versus ...

In cholangiocarcinoma, published case series have also reported secondary IDH1 mutations that block ivosidenib binding and isoform switching (ie, acquired IDH2 mutations) as

Expert opinion: According to the results of phase I studies and the recently published ClarIDHy phase III trial, the IDH-1 inhibitor ivosidenib seems to be associated with a

These data, coupled with supportive quality of life data and a tolerable safety profile, demonstrate the clinical benefit of ivosidenib for

In the trial, 185 patients with advanced cholangiocarcinoma and IDH1-mutant cholangiocarcinoma were randomly assigned to 500 mg oral ivosidenib daily (n = 124) or

Ivosidenib is the first IDH1 inhibitor which significantly improved progression-free survival (PFS) (2.7 vs 1.4 months) and overall survival (OS) (10.3 vs 5.1 months [adjusted

In a phase 1 dose-escalation and expansion study, ivosidenib showed promising progression-free survival and overall survival outcomes, combined with a favourable safety and

Based on the results of various clinical trials, ivosidenib was approved for acute myeloid leukemia harboring the IDH1 mutation. It has also been shown that ivosidenib was

The FDA has approved ivosidenib for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation,

Based on the results of various clinical trials, ivosidenib was approved for acute myeloid leukemia harboring the IDH1 mutation. It has also been shown that ivosidenib was effective in patients

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia and previously treated locally advanced or

We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg

Ivosidenib (Tibsovo ®), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the